Eli Lilly Expands Gene Therapy Pipeline with $7 Billion Kelonia Therapeutics Acquisition

Eli Lilly and Company (LLY) announced on Monday its acquisition of Kelonia Therapeutics, a clinical-stage biotechnology firm specializing in pioneering in vivo gene delivery systems. The move signals a strategic push by the pharmaceutical giant to advance its capabilities in genetic medicine. Kelonia has developed a proprietary in vivo gene placement system utilizing specially engineered lentiviral-based particles. This technology is designed to selectively enter T-cells inside the patient's body, effectively allowing the body to generate its own chimeric antigen receptor (CAR) T-cells to treat underlying diseases, bypassing some of the complexities of traditional ex vivo therapies. A central asset in the acquisition is Kelonia's lead program, KLN-1010. This investigational, one-time intravenous gene therapy presented encouraging early results and demonstrated promising tolerability during the plenary session of the 2025 American Society of Hematology Annual Meeting, providing critical initial clinical validation. Under the financial terms of the agreement, Lilly will provide an upfront cash payment of $3.25 billion. The total deal value could reach $7 billion based on the achievement of specific clinical, regulatory, and commercial milestones. The transaction is expected to close in the second half of 2026. Following the announcement, LLY shares were trading at $925.34, reflecting a marginal decline of 0.19% on the New York Stock Exchange.